Regulation of gene expression in ovarian cancer cells by luteinizing hormone receptor expression and activation

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Cui, Juan ^a   Miner, Brooke M ^a   Eldredge, Joanna B ^a   Warrenfeltz, Susanne W ^a   Dam, Phuongan ^a   Xu, Ying ^a,b,c   Puett, David ^a  

^a University of Georgia   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c JILIN UNIVERSITY   (China)

Author keywords

Gonadotropin; Luteinizing hormone; Luteinizing hormone receptor; Microarray; Ovarian cancer; SKOV3 cells

Indexed keywords

CELL NUCLEUS RECEPTOR; ENDOTHELIN 1; G PROTEIN COUPLED RECEPTOR; GONADOTROPIN; GROWTH FACTOR; LUTEINIZING HORMONE; LUTEINIZING HORMONE RECEPTOR; PROTEIN C JUN; RECEPTOR SUBTYPE; SOMATOMEDIN B; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR; APOPTOSIS REGULATORY PROTEIN; CARRIER PROTEIN; CELL RECEPTOR; HYBRID PROTEIN; MESSENGER RNA; RNA; SIGNAL PEPTIDE; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL GROWTH; CELL STRAIN SKOV 3; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; OVARY CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; UPREGULATION; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; GENETIC TRANSCRIPTION; GENETICS; IN VITRO STUDY; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUTEINIZING HORMONE; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, LH; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 79959617947     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-280     Document Type: Article

References (62)

1. American Cancer Society. , http://www.cancer.org
2. Ries LAG MD, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK, . eds SEER Cancer Statistics Review. 2008, National Cancer Institute, Bethesda M, eds.
3. Lancaster JM, Carney ME, Futreal PA. BRCA 1 and 2--A Genetic Link to Familial Breast and Ovarian Cancer. Medscape Womens Health 1997, 2(2):7.
4. Slot KA, de Boer-Brouwer M, Houweling M, Vaandrager AB, Dorrington JH, Teerds KJ. Luteinizing hormone inhibits Fas-induced apoptosis in ovarian surface epithelial cell lines. J Endocrinol 2006, 188(2):227-239. 10.1677/joe.1.06087, 16461549.
5. Casagrande JT, Louie EW, Pike MC, Roy S, Ross RK, Henderson BE. "Incessant ovulation" and ovarian cancer. Lancet 1979, 2(8135):170-173.
6. Choi JH, Wong AS, Huang HF, Leung PC. Gonadotropins and ovarian cancer. Endocr Rev 2007, 28(4):440-461. 10.1210/er.2006-0036, 17463396.
7. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992, 136(10):1212-1220.
8. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999, 354(9190):1586-1590. 10.1016/S0140-6736(99)05203-4, 10560672.
9. Brekelmans CT. Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol 2003, 15(1):63-68. 10.1097/00001703-200302000-00010, 12544504.
10. Leung PC, Choi JH. Endocrine signaling in ovarian surface epithelium and cancer. Hum Reprod Update 2007, 13(2):143-162.
11. Richards JS, Pangas SA. The ovary: basic biology and clinical implications. J Clin Invest 2010, 120(4):963-972. 10.1172/JCI41350, 2846061, 20364094.
12. Powell BL, Piersma D, Kevenaar ME, van Staveren IL, Themmen AP, Iacopetta BJ, Berns EM. Luteinizing hormone signaling and breast cancer: polymorphisms and age of onset. J Clin Endocrinol Metab 2003, 88(4):1653-1657. 10.1210/jc.2002-021585, 12679452.
13. Ascoli M, Puett D. The Gonadotropins and Their Receptors. Yen and Jaffee's Reproductive Endocrinology 2009, 35-55. Philadelphia: Elsevier Publ. Co, Strauss IJ, Barbieri R, 6.
14. Mandai M, Konishi I, Kuroda H, Fujii S. LH/hCG action and development of ovarian cancer--a short review on biological and clinical/epidemiological aspects. Mol Cell Endocrinol 2007, 269(1-2):61-64. 10.1016/j.mce.2006.11.014, 17353087.
15. Huhtaniemi I. Are gonadotrophins tumorigenic--a critical review of clinical and experimental data. Mol Cell Endocrinol 2010, 329(1-2):56-61. 10.1016/j.mce.2010.04.028, 20471448.
16. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 1997, 67(6):1005-1012. 10.1016/S0015-0282(97)81431-8, 9176436.
17. Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, Bergh T, Hagenfeldt K, Janson PO, Nilsson S, Persson I. Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril 2009, 91(4):1152-1158. 10.1016/j.fertnstert.2008.01.073, 18371964.
18. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
19. Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 2001, 172(1-2):213-222. 10.1016/S0303-7207(00)00340-3, 11165055.
20. Warrenfeltz SW, Lott SA, Palmer TM, Gray JC, Puett D. Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells. Mol Cancer Res 2008, 6(11):1775-1785. 10.1158/1541-7786.MCR-08-0214, 19010824.
21. Ji X, Tang J, Halberg R, Busam D, Ferriera S, Pena MM, Venkataramu C, Yeatman TJ, Zhao S. Distinguishing between cancer driver and passenger gene alteration candidates via cross-species comparison: a pilot study. BMC Cancer 2010, 10:426. 10.1186/1471-2407-10-426, 2927548, 20707908.
22. Affymetrix Alternative Transcript Analysis Methods for Exon Arrays. 2005, 10-11. Affymetrix.
23. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998, 95(25):14863-14868. 10.1073/pnas.95.25.14863, 24541, 9843981.
24. Kohonen T. Self-organized formation of topologically correct feature maps. Biological Cybernetics 1982, 43:59-69.
25. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000, 28(1):27-30. 10.1093/nar/28.1.27, 102409, 10592173.
26. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, et al. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 2009, 22(9):1243-1250. 10.1038/modpathol.2009.92, 2736318, 19525924.
27. GeneGo Ingenuity Pathways analysis(IPA). 2000, GeneGo.
28. Holder JW, Elmore E, Barrett JC. Gap junction function and cancer. Cancer Res 1993, 53(15):3475-3485.
29. Sjolund J, Manetopoulos C, Stockhausen MT, Axelson H. The Notch pathway in cancer: differentiation gone awry. Eur J Cancer 2005, 41(17):2620-2629. 10.1016/j.ejca.2005.06.025, 16239105.
30. Wierman ME. Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ 2007, 31(1):26-33. 10.1152/advan.00086.2006, 17327579.
31. Sullivan DA, Jensen RV, Suzuki T, Richards SM. Do sex steroids exert sex-specific and/or opposite effects on gene expression in lacrimal and meibomian glands?. Mol Vis 2009, 15:1553-1572. 2728565, 19693291.
32. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277(5327):815-818. 10.1126/science.277.5327.815, 9242610.
33. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol 1999, 17:781-828. 10.1146/annurev.immunol.17.1.781, 10358774.
34. Weeks II JL CM The cAMP-Specific Phosphodiesterases: A Class of Diverse Enzymes that Define the Properties and Localization of cAMP Signals. In Handbook of Cell Signaling 2010, 2:1415-1423. New York: Academic Press, Bradshaw RA D, EA, Weeks II JL CM.
35. Asschert JG, Vellenga E, Ruiters MH, de Vries EG. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer 1999, 82(2):244-249. 10.1002/(SICI)1097-0215(19990719)82:2<244::AID-IJC15>3.0.CO;2-N, 10389759.
36. Chou CH, Wei LH, Kuo ML, Huang YJ, Lai KP, Chen CA, Hsieh CY. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor. Carcinogenesis 2005, 26(1):45-52.
37. Schwartz BM, Hong G, Morrison BH, Wu W, Baudhuin LM, Xiao YJ, Mok SC, Xu Y. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol 2001, 81(2):291-300. 10.1006/gyno.2001.6124, 11330965.
38. Cui J, Liu Q, Puett D, Xu Y. Computational prediction of human proteins that can be secreted into the bloodstream. Bioinformatics 2008, 24(20):2370-2375. 10.1093/bioinformatics/btn418, 2562011, 18697770.
39. Omenn GS, States DJ, Adamski M, Blackwell TW, Menon R, Hermjakob H, Apweiler R, Haab BB, Simpson RJ, Eddes JS, et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5(13):3226-3245. 10.1002/pmic.200500358, 16104056.
40. Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008, 40(8):1443-1451. 10.1016/j.biocel.2008.01.022, 18325824.
41. Bhalla A, Haque S, Taylor I, Winslet M, Loizidou M. Endothelin receptor antagonism and cancer. Eur J Clin Invest 2009, (39 Suppl 2):74-77.
42. Rosano L, Spinella F, Bagnato A. The importance of endothelin axis in initiation, progression, and therapy of ovarian cancer. Am J Physiol Regul Integr Comp Physiol 2010, 299(2):R395-404. 10.1152/ajpregu.00304.2010, 20538897.
43. Rayhman O, Klipper E, Muller L, Davidson B, Reich R, Meidan R. Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells. Cancer Res 2008, 68(22):9265-9273. 10.1158/0008-5472.CAN-08-2093, 19010899.
44. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, Jiang WG. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 2005, 7(4):R402-410. 10.1186/bcr1022, 1175055, 15987445.
45. Zaina S, Pettersson L, Ahren B, Branen L, Hassan AB, Lindholm M, Mattsson R, Thyberg J, Nilsson J. Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model. J Biol Chem 2002, 277(6):4505-4511. 10.1074/jbc.M108061200, 11726660.
46. Choi JH, Choi KC, Auersperg N, Leung PC. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res 2006, 66(7):3912-3920. 10.1158/0008-5472.CAN-05-1785, 16585220.
47. Lau MT, Wong AS, Leung PC. Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 2010, 151(7):2985-2993. 10.1210/en.2009-1318, 20392831.
48. Haouzi D, Assou S, Mahmoud K, Hedon B, De Vos J, Dewailly D, Hamamah S. LH/hCGR gene expression in human cumulus cells is linked to the expression of the extracellular matrix modifying gene TNFAIP6 and to serum estradiol levels on day of hCG administration. Hum Reprod 2009, 24(11):2868-2878. 10.1093/humrep/dep263, 19625307.
49. Friedmann S, Dantes A, Amsterdam A. Ovarian transcriptomes as a tool for a global approach of genes modulated by gonadotropic hormones in human ovarian granulosa cells. Endocrine 2005, 26(3):259-265. 10.1385/ENDO:26:3:259, 16034180.
50. Grondahl ML, Borup R, Lee YB, Myrhoj V, Meinertz H, Sorensen S. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. Fertil Steril 2009, 91(5):1820-1830. 10.1016/j.fertnstert.2008.02.137, 18439596.
51. Lee PS, Buchan AM, Hsueh AJ, Yuen BH, Leung PC. Intracellular calcium mobilization in response to the activation of human wild-type and chimeric gonadotropin receptors. Endocrinology 2002, 143(5):1732-1740. 10.1210/en.143.5.1732, 11956155.
52. Leithe E, Sirnes S, Omori Y, Rivedal E. Downregulation of gap junctions in cancer cells. Crit Rev Oncog 2006, 12(3-4):225-256.
53. Kuroda H, Mandai M, Konishi I, Tsuruta Y, Kusakari T, Kariya M, Fujii S. Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and hCG inhibits apoptosis of OSE cells via up-regulation of insulin-like growth factor-1. Int J Cancer 2001, 91(3):309-315. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1060>3.0.CO;2-0, 11169952.
54. Ravi R, Bedi A. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res 2002, 62(15):4180-4185.
55. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) 2006, 110(3):279-291.
56. Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, Revelo M. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 2006, 20(10):2315-2325. 10.1210/me.2006-0048, 16762975.
57. Wisdom R, Johnson RS, Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999, 18(1):188-197. 10.1093/emboj/18.1.188, 1171114, 9878062.
58. Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci USA 1997, 94(7):2776-2778. 10.1073/pnas.94.7.2776, 34145, 9096291.
59. Shapiro AM, Suarez-Pinzon WL, Power R, Rabinovitch A. Combination therapy with low dose sirolimus and tacrolimus is synergistic in preventing spontaneous and recurrent autoimmune diabetes in non-obese diabetic mice. Diabetologia 2002, 45(2):224-230. 10.1007/s00125-001-0745-x, 11935154.
60. Janssens JP, Russo J, Russo I, Michiels L, Donders G, Verjans M, Riphagen I, Van den Bossche T, Deleu M, Sieprath P. Human chorionic gonadotropin (hCG) and prevention of breast cancer. Mol Cell Endocrinol 2007, 269(1-2):93-98. 10.1016/j.mce.2006.06.015, 17386970.
61. Rao Ch V, Li X, Manna SK, Lei ZM, Aggarwal BB. Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-kappaB and AP-1 activation. J Biol Chem 2004, 279(24):25503-25510. 10.1074/jbc.M400683200, 15044447.
62. Cui J, Chen Y, Chou WC, Sun L, Chen L, Suo J, Ni Z, Zhang M, Kong X, Hoffman LL, et al. An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucleic Acids Res 2011, 39(4):1197-1207. 10.1093/nar/gkq960, 3045610, 20965966.